Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 5:258:115582.
doi: 10.1016/j.ejmech.2023.115582. Epub 2023 Jun 25.

Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915

Affiliations

Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915

Carissa S Hampton et al. Eur J Med Chem. .

Abstract

Estrogen-related receptors (ERR) are an orphan nuclear receptor sub-family that play a critical role in regulating gene transcription for several physiological processes including mitochondrial function, cellular energy utilization and homeostasis. They have also been implicated to play a role in several pathological conditions. Herein, we report the identification, synthesis, structure-activity relationships and pharmacological evaluation of a new chemical series of potent pan-ERR agonists. This template was designed for ERRγ starting from the known acyl hydrazide template and compounds such as agonist GSK-4716 employing a structure-based drug design approach. This led to the preparation of a series of 2,5-disubstituted thiophenes from which several were found to be potent agonists of ERRγ in cell-based co-transfection assays. Additionally, direct binding to ERRγ was established through 1H NMR protein-ligand binding experiments. Compound optimization revealed that the phenolic or aniline groups could be replaced with a boronic acid moiety, which was able to maintain activity and demonstrated improved metabolic stability in microsomal in vitro assays. Further pharmacological evaluation of these compounds showed that they had roughly equivalent agonist activity on ERR isoforms α and β representing an ERR pan-agonist profile. One potent agonist, SLU-PP-915 (10s), which contained a boronic acid moiety was profiled in gene expression assays and found to significantly upregulate the expression of ERR target genes such as peroxisome-proliferator activated receptor γ co-activators-1α, lactate dehydrogenase A, DNA damage inducible transcript 4 and pyruvate dehydrogenase kinase 4 both in vitro and in vivo.

Keywords: 2 5-disubstituted thiophenes; Boronic acid; Estrogen-related receptor; Nuclear receptor; Pan-agonist.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:John K Walker reports financial support was provided by National Institutes of Health. Thomas P. Burris reports financial support was provided by National Institutes of Health. John K. Walker has patent #WO2019036562; Heteroaromatics as ERR inverse agonists and their preparation licensed to Myonid Therapeutics. Thomas P. Burris has patent #WO2019036562; Heteroaromatics as ERR inverse agonists and their preparation licensed to Myonid Therapeutics. Carissa Hampton has patent #WO2019036562; Heteroaromatics as ERR inverse agonists and their preparation licensed to Myonid Therapeutics. Keith Haynes has patent #WO2019036562; Heteroaromatics as ERR inverse agonists and their preparation licensed to Myonid Therapeutics. Kristine Griffett has patent #WO2019036562; Heteroaromatics as ERR inverse agonists and their preparation licensed to Myonid Therapeutics. Cyrielle Billon has patent #WO2019036562; Heteroaromatics as ERR inverse agonists and their preparation licensed to Myonid Therapeutics. Sadichha Situala has patent #WO2019036562; Heteroaromatics as ERR inverse agonists and their preparation licensed to Myonid Therapeutics. Founders in Myonid Therapeutics which is trying to develop ERR modulators as novel therapeutics (J.K.W. & T.P.B)

Figures

Figure 1.
Figure 1.
Representative ERR synthetic ligands: ERRγ inverse agonists 4-OHT(1) and DES(2), ERRβ/γ agonist GSK-4716 (3), ERRγ agonist 4 and ERRα agonist 5
Figure 2.
Figure 2.
Structure and ERR co-transfection data for Pan-ERR agonist SLU-PP-332 (6)
Figure 3.
Figure 3.
Two-dimensional representation of GSK-4716 (3) bound in the LBD of ERRγ, PDB:2GPP
Figure 4.
Figure 4.
General structure-based design strategy to develop new ERR agonists
Figure 5.
Figure 5.
1H-NMR methyl region spectra of ERRγ with 0.5% DMSO-d6. where the blue line represents vehicle alone and the red line is protein + 1.05:1 molar equivalence of ligand. A) protein + SR-9238 B) protein + 6 C) Protein + 10s D) Protein + 12e
Figure 6.
Figure 6.
Molecular modeling of key compounds docked in the ligand binding domain of ERRγ obtained from the X-ray structure of 3 (PGB:2GPP). Compounds are shown in green. A) 9b docked in the anticipated compound 6 like orientation B) 9b docked in the ‘flipped’ conformation C) Compound 10s in the compound 6 like orientation. D) 10s in the ‘flipped’ conformation
Figure 7.
Figure 7.
Gene expression in C2C12 myoblast cells treated with several compounds at 5uM for 24hrs. A. Relative gene expression levels for PGC1α vs control B. Relative gene expression levels for PDK4 vs control C. Relative gene expression levels for LDHA vs control. n=3 per condition, * p<0.05, ** p<0.01.
Figure 8:
Figure 8:
ERR agonist SLU-PP-915 (10s) induces expression of ERR target genes in vivo: A) Gene expression from muscle from mice treated with SLU-PP-915 (20mg/kg, I.P) for 1h (n=3 per group). B. Running time and distance from mice 1h after being treated with SLU-PP-915 (20mg/kg, I.P). * p<0.05, ** p<0.01.
Scheme 1.
Scheme 1.
Synthesis of C(5)-hydroxyphenyl thiophene analogsa Reaction conditions: (a) RNH2, DIPEA, TBTU, DMF (b) 4-hydroxyphenyl boronic acid, Pd(PPh3)4; K2CO3, DMF, 90 °C
Scheme 2.
Scheme 2.
Synthesis of 2,5-disubstituted thiophene analogsa Reaction conditions: (a) Boronic acid, Pd(PPh3)4; K2CO3, EtOH or DMF, heat or Boronic acid, Pd(dppf)CI2-CH2CI2; Na2CO3, dioxane, 80°C
Scheme 3
Scheme 3
Synthesis of 2,5-disubstituted thiophene analogs with the HBD group in the amide substituent a a Reaction conditions: (a) RNH2, DIPEA, TBTU, DMF (b) Boronic acid, Pd(PPh3)4; K2CO3, DMF, heat

Similar articles

Cited by

References

    1. Gallastegui N; Mackinnon JA; Fletterick RJ; Estebanez-Perpina E, Advances in our structural understanding of orphan nuclear receptors. Trends Biochem Sci 2015, 40 (1), 25–35. - PubMed
    1. Mazaira GI; Zgajnar NR; Lotufo CM; Daneri-Becerra C; Sivils JC; Soto OB; Cox MB; Galigniana MD, The nuclear receptor field: a historical overview and future challenges. Nucl. Recept. Res 2018, 5, 101320. - PMC - PubMed
    1. Horard B; Vanacker JM, Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. Journal of Mol. Endocrinol 2003, 31 (3), 349–357. - PubMed
    1. Greschik H; Wurtz J-M; Sanglier S; Bourguet W; van Dorsselaer A; Moras D; Renaud J-P, Structural and Functional Evidence for Ligand-Independent Transcriptional Activation by the Estrogen-Related Receptor 3. Mol. Cell 2002, 9 (2), 303–313. - PubMed
    1. Hong H; Yang L; Stallcup MR, Hormone-independent Transcriptional Activation and Coactivator Binding by Novel Orphan Nuclear Receptor ERR3. J. Biol. Chem 1999, 274 (32), 22618–22626. - PubMed

LinkOut - more resources